ClinicalTrials.gg
RecruitingNCT07448103INROBICSUpdated Jul 23, 2026

Hospital and Home Rehabilitation Based on Social Care Robotics and Artificial Intelligence for Pediatric Patients

An interventional study of Robot-assisted, gamified pediatric upper-limb rehabilitation (hybrid clinic + home program) in Acquired Brain Injury, sponsored by Inrobics Social Robotics, S.L.. Recruiting at 1 site in Spain. Open to participants aged 7 Years to 16 Years. Per ClinicalTrials.gov, last updated 2026-07-23.

Sponsored by Inrobics Social Robotics, S.L. · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Apr 2026; still recruiting 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
7 Years to 16 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 43 studies in Brain Injuries with a site in Spain — 11 open to participants now, 13 under way, none of them phase 3. Brain Injuries · Spain.

Planned enrollment
12th of 30
30 · median 30
Started
2026
with 4 others
No phase
27 of 43
8 open now
Primary completion
2027-02
later than 6 of 12 live
Registered
39th of 43
by date

Among the 43 studies in Brain Injuries with a site in Spain, this one is the 12th largest by planned enrollment of the 30 interventional ones that give a count, is one of 5 that started in 2026, is one of 27 with no phase, reaches primary completion later than 6 of the 12 other live ones, and was the 39th registered.

Brain Injuries

947 studies on the registry are indexed under Brain Injuries; 234 are open to participants now.

Browse Brain Injuries studies →

Open to participants now

11 of the 43 studies in Brain Injuries with a site in Spain are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 152 Brain Injuries studies recruiting now, 77 (51%) set no upper age limit and 53 (35%) stop at 75 or younger; 38 take children under 18; 23 take healthy volunteers.

This study: 7 Years to 16 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Brain Injuries with a site in Spain, or all of them as a file.
02

Study summary

This study describes a prospective, longitudinal, randomized controlled trial evaluating Inrobics Rehab, a CE-marked Class I medical device (reg. RPS/777/2021) that combines socially assistive robotics with virtual training for pediatric rehabilitation. The trial will assess usability, user experience, and clinical effectiveness. It is based on the premise that an interactive, motivating, monitored digital environment can improve engagement and adherence while enabling objective tracking of progress. The main hypothesis is that Inrobics Rehab will enhance motor, cognitive, and socio-emotional outcomes in children with acquired brain injury (ABI) and will be well accepted by users.

Participants will be children aged 7-16 years with confirmed ABI, adequate comprehension to follow instructions, clinical stability, and the ability to maintain sitting (with or without supports). Exclusion criteria include unstable upper-limb orthopedic injuries; severe pain, rigidity, or severe upper-limb spasticity; severe cardiopulmonary disease requiring constant monitoring; abnormal pre-ABI response to exertion; severe visual or cognitive impairment; disabling psychiatric disease; or any condition preventing safe participation. Additional safeguards are included due to the pediatric/vulnerable population.

Thirty participants will be recruited at Hospital Infantil Universitario Niño Jesús and split into two etiological cohorts (15 oncological, 15 non-oncological). Eligible patients will be enrolled by convenience sampling and randomized within each cohort to experimental or control arms (about half per arm) using sequentially numbered sealed envelopes based on a computer-generated random list. Outcome assessors are intended to remain blinded to allocation.

The experimental arm completes 30 sessions over 5 weeks: 15 supervised in-hospital sessions (Inrobics Rehab Clinic) and 15 home-based sessions (Inrobics Rehab Virtual). Hospital sessions are delivered three times per week for 30 minutes. Home sessions are completed three times per week on a tablet, guided by an interactive avatar, with gamification and automatic collection of performance metrics; a ±2-week window is allowed only to make up missed sessions. The control arm receives no intervention and undergoes evaluations at comparable timepoints; after study completion, controls may access the virtual platform for 1-3 months or complete the full program.

Assessments occur at baseline, post-intervention, and 3-month follow-up, with session-level monitoring of satisfaction, fatigue and/or pain. Heart rate is monitored only during hospital sessions (Polar Verity Sense). Outcomes include motor function (TCMS, Box \& Block, ABILHAND-Kids), neuropsychological and emotional measures (attention, working memory, depression/anxiety, executive functioning), health perception and burden (EQoL-5D-Y5L, pain VAS, fatigue, caregiver burden), and usability/engagement analytics (accuracy, reaction time, engagement, execution speed). Data will be pseudonymized, stored securely with restricted access, and retained for at least 10 years (or longer if required by medical device regulations).

Read the detailed description

This study describes a randomized controlled clinical trial designed to evaluate the usability, user experience, and clinical effectiveness of Inrobics Rehab, a pediatric rehabilitation solution based on Socially Assistive Robotics (SAR) and Artificial Intelligence, in children and adolescents with Acquired Brain Injury (ABI) aged 7-16 years. The rationale is that SAR and virtual training can provide an interactive and motivating environment that may increase engagement and adherence, while enabling controlled, monitored exercises and objective follow-up of progress; however, evidence in pediatric ABI remains limited. The study hypothesis is that Inrobics Rehab can improve motor, cognitive, and socio-emotional outcomes in this population, while delivering a positive user experience with good usability and high adherence.

The study is planned as an experimental, longitudinal, prospective, controlled, randomized clinical trial using a CE-marked medical device (Inrobics Rehab; CE Class I, registration no. RPS/777/2021). It is embedded in a 36-month collaborative research project involving INROBICS, the Hospital Nacional de Parapléjicos, and the Hospital Infantil Universitario Niño Jesús (HIUNJ), where HIUNJ plays a central role in patient selection, clinical assessments, delivery of therapy sessions, and clinical data collection in a real-world hospital setting.

Participants will be pediatric patients with confirmed ABI receiving care at the HIUNJ Rehabilitation Service. Eligibility requires: age 7-16 years; sufficient comprehension to follow basic instructions and participate actively; confirmed acquired brain injury; clinical stability to engage in therapy; and ability to maintain independent sitting, with or without assistive supports (e.g., belts, wedges, trunk supports). Key exclusion criteria include unstable orthopedic injuries in the upper limbs (e.g., non-consolidated fractures or unstable osteosynthesis), severe pain/rigidity and/or severe upper-limb spasticity, severe pulmonary or cardiac disease requiring constant monitoring during exercise, a history of abnormal response to physical effort prior to ABI, severe visual impairment, severe cognitive impairment and/or disabling psychiatric disease, or any other condition judged by the medical team to prevent safe participation. The protocol emphasizes enhanced protection measures for this vulnerable population through reinforced consent/assent procedures, strict selection criteria, monitoring, and additional risk minimization.

A total sample of 30 pediatric ABI participants is planned, split into two etiological cohorts to support balanced comparisons: 15 with oncological etiology and 15 with non-oncological etiology. Initial selection is by convenience sampling among eligible patients routinely followed at HIUNJ; subsequently, within each etiological subgroup, participants are randomly allocated to an experimental or control arm, with approximately half in each arm. Randomization is implemented using sequentially numbered sealed envelopes containing group assignment (control vs intervention), based on a computer-generated random list; hospital evaluators remain blinded to group allocation to support objectivity in outcome collection. The protocol acknowledges that the theoretically estimated sample size to detect moderate effects would be larger, but justifies feasibility constraints and the relevance of the proposed sample in the context of pediatric SAR studies.

The experimental intervention consists of a structured rehabilitation program delivered through Inrobics Rehab Clinic (hospital) and Inrobics Rehab Virtual (home). The program includes 30 total sessions over 5 weeks of active intervention, distributed equally between 15 in-hospital sessions and 15 home-based virtual sessions, delivered in an alternating manner (weeks combining clinic and virtual work) to allow progressive adaptation while maintaining continuous clinical follow-up. Each hospital session lasts 30 minutes, with a planned frequency of 3 sessions per week, programmed and directed by a professional using the clinical platform and supervised throughout. In the home phase, participants complete 3 sessions per week via the virtual platform on a tablet, following exercises prescribed by the clinician and guided by an interactive virtual avatar; gamification elements are included to enhance motivation and participation, and the system records objective metrics to support monitoring of therapeutic progress and adaptation. A contingency window of ±2 additional weeks is allowed solely to recover missed sessions due to justified absences, without extending beyond this limit, to preserve a homogeneous "dose" of intervention and the internal validity of the design.

The control arm receives no therapeutic intervention within the trial; control participants complete the same evaluation schedule as the experimental group to enable between-group comparisons and help isolate the effect of the robotics/virtual intervention from external factors. To ensure fairness, the protocol includes a post-trial access option for control participants: after the clinical trial ends, they may access Inrobics Rehab Virtual for 1-3 months through a temporary license, or opt to undergo the full intervention program (hospital + home phases) if desired. At study completion, all participants in both groups receive an individualized final report summarizing assessment results over the program.

Outcome assessment is scheduled at baseline (pre-intervention), immediately after the intervention period (post-intervention at \~5 weeks for the intervention arm; at a comparable timepoint for controls), and at 3 months follow-up to determine whether observed changes are maintained. In addition, during the intervention, session-by-session ratings of satisfaction, fatigue, and/or pain are collected (hospital and home), and user-experience parameters are continuously recorded by the platform; heart rate is monitored only during hospital sessions. A dedicated Case Report Form (CRF) is included as an annex to standardize data capture and organization.

The protocol defines a broad set of outcomes covering motor performance, cognition/emotional status, health perception and burden, and usability/user experience. Motor efficacy is assessed using standardized measures including trunk control (Trunk Control Measurement Scale, TCMS), manual dexterity (Box \& Block, complemented by Leap Motion measures), and manual function (ABILHAND-Kids, with optional Jebsen-Taylor), as well as dominance (Edinburgh inventory) and upper-limb strength (Daniels and/or dynamometry). Neuropsychological and emotional domains include visual attention (perception/difference or "faces" tests), working memory (WISC-V digit span), depressive symptoms (Children's Depression Inventory for those under 14), anxiety (STAIC), and executive functioning (EFE inventory). Health perception and burden include pediatric quality of life (EQoL-5D-Y5L), pain (VAS), fatigue (EPInfant), and caregiver burden (Zarit). Usability and user experience are examined using both questionnaires and platform analytics, such as motor accuracy, reaction time, engagement (e.g., whether the user remains oriented toward the platform/tablet), aggregated performance metrics, and execution speed; physiological response to effort is assessed with heart-rate monitoring using Polar Verity Sense during hospital sessions. Satisfaction is assessed via SAM (child) and QUEST 2.0 (caregiver), and involvement/adherence-related constructs include a Hopkins measure of engagement with the training program.

Planned analyses include descriptive statistics and inferential comparisons across timepoints and between groups, selecting methods based on variable type and distribution, with standard significance thresholds; the protocol also identifies potential biases such as limited sample size, subjectivity in self-reported scales, and potential attrition particularly during the home phase.

Ethical conduct and data protection are addressed in line with relevant regulations and the specific needs of pediatric participants. The study is conducted according to the Declaration of Helsinki, and participation requires formal informed consent (with the option to withdraw at any time without affecting usual care). Data are pseudonymized using a sequential alphanumeric code assigned by inclusion order; all questionnaires, clinical measures, physiological records, and platform data are labeled only with this identifier, while the code-to-identity link is stored separately with restricted access. Pseudonymized datasets for analysis are stored in the institutional OneDrive environment with restricted, credential-based access, and cross-site data sharing is limited to pseudonymized information through controlled shared folders with the sponsor (INROBICS). Documentation generated for the clinical investigation is retained for at least 10 years after study completion (and potentially longer depending on applicable medical device regulatory requirements and market placement), with measures to ensure integrity, accessibility, and protection against loss, alteration, or unauthorized access.

03

Conditions studied

  • Acquired Brain Injury

Keywords

  • Acquired Brain Injury
  • Social Robots
  • Neurorehabilitation
  • Children with Disability
  • Telemedicine
  • Oncology
04

Who can participate

Ages eligible
7 Years to 16 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Children/adolescents 7-16 years with confirmed acquired brain injury
  • Clinically stable
  • Able to understand and follow basic instructions
  • Able to maintain sitting independently (with or without postural supports)

Exclusion criteria

Exclusion Criteria:

  • Unstable upper-limb orthopedic injuries (e.g., non-consolidated fractures/unstable osteosynthesis).
  • Severe pain/rigidity and/or severe upper-limb spasticity
  • Severe pulmonary or cardiac disease requiring constant monitoring
  • History of abnormal response to exertion prior to acquired brain injury
  • Severe visual impairment, severe cognitive impairment or disabling psychiatric disease, or any other condition that makes participation unsafe or not feasible per the medical team.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Inrobics

    Participants assigned to the intervention arm will complete a structured pediatric rehabilitation program totaling 30 sessions over \~5 weeks. They will alternate 15 supervised in-hospital sessions (Inrobics Rehab Clinic; 30 minutes, 3 sessions/week) with 15 home-based virtual sessions (Inrobics Rehab Virtual; 3 sessions/week) performed on a tablet and guided by an interactive avatar. The virtual training incorporates gamified tasks and automatically records objective performance metrics (e.g., accuracy, reaction time, execution speed) to support clinician follow-up and individualized progression. A ±2-week make-up window is allowed only to recover missed sessions due to justified absences, without extending beyond that limit.

    Device: Robot-assisted, gamified pediatric upper-limb rehabilitation (hybrid clinic + home program)

  • No intervention
    No Inrobics

    Participants randomized to the control arm will receive no study intervention and will continue with usual care outside the trial. They will complete the same assessment schedule as the intervention group (baseline, post-intervention timepoint, and 3-month follow-up) to allow comparison of outcomes over time. After trial completion, control participants may be offered temporary access to Inrobics Rehab Virtual (about 1-3 months) or the option to undertake the full program, depending on preference and availability.

Interventions

  • DeviceRobot-assisted, gamified pediatric upper-limb rehabilitation (hybrid clinic + home program)

    The intervention is a hybrid pediatric rehabilitation program delivered through a socially assistive robotics-based virtual training platform. Participants complete 30 sessions over \~5 weeks, alternating 15 supervised in-hospital sessions (30 minutes, 3/week) led by a therapist using the clinical version, with 15 home-based sessions (3/week) on a tablet using the virtual version guided by an avatar. Training consists of gamified upper-limb and postural control activities prescribed and adjusted by the clinician, with automatic logging of objective performance (e.g., accuracy, reaction time, execution speed, engagement) to support monitoring and progression. A ±2-week window is allowed only to make up missed sessions due to justified absences; heart rate is recorded during hospital sessions.

06

What researchers measure

Primary outcomes

  1. Change from baseline in Trunk Control Measurement Scale (TCMS) Score

    Trunk control will be assessed using TCMS, a clinical scale evaluating static and dynamic sitting balance and selective trunk movement control. Higher scores indicate better trunk control.

    Time frame: Baseline (pre-intervention), end of intervention (post; after 5 weeks), and 3-monthfollow-up.

Secondary outcomes

  1. Change from baseline in Box and Block Test Score.

    Manual dexterity will be assessed using the Box and Block Test, which measures the number of blocks transferred within a fixed time period. Higher scores indicate better manual dexterity.

    Time frame: Baseline, week 5, and month 3.

  2. Change from baseline in upper limb movement metrics assessed by Leap Motion.

    Upper limb movement during standardized motor tasks will be recorded using the Leap Motion sensor. Metrics are automatically captured by the system.

    Time frame: Baseline, week 5, and month 3.

  3. Change from baseline in manual ability assessed by ABILHAND-Kids.

    Manual ability in daily activities will be assessed using the ABILHAND-Kids questionnaire completed by caregivers. Higher scores indicate better perceived manual ability.

    Time frame: Baseline, week 5, and month 3.

  4. Change from baseline in hand function assessed by the Jebsen-Taylor Hand Function Test.

    Hand function will be assessed using the Jebsen-Taylor Hand Function Test, which measures the time (in seconds) required to complete standardized manual tasks. Shorter completion times indicate better hand function.

    Time frame: Baseline, week 5, and month 3.

  5. Handedness assessed by the Edinburgh Handedness Inventory.

    Hand dominance will be assessed using the Edinburgh Handedness Inventory at study entry.

    Time frame: Baseline.

  6. Change from baseline in upper limb muscle strength assessed by manual muscle testing (Daniels).

    Upper limb muscle strength will be assessed using the Daniels manual muscle testing scale. Muscle strength is graded from 0 (no visible contraction) to 5 (normal strength against full resistance). Higher scores indicate greater strength.

    Time frame: Baseline, week 5, and month 3.

  7. Change from baseline in upper limb muscle strength assessed by Dynamometry.

    Upper limb muscle strength will be assessed using dynamometry during clinical evaluation. Higher values indicate greater muscle strength.

    Time frame: Baseline, week 5, and month 3.

  8. Change from baseline in visual attention assessed by the "Faces Test".

    Visual attention will be assessed using the "Faces Test". Higher scores indicate better visual attention performance.

    Time frame: Baseline, week 5, and month 3.

  9. Change from baseline in working memory assessed by WISC-V Digit Span.

    Working memory will be assessed using the Digit Span subtest of the Wechsler Intelligence Scale for Children (WISC-V). Higher scores indicate better working memory performance.

    Time frame: Baseline, week 5, and month 3.

  10. Change from baseline in depressive symptoms assessed by the Children's Depression Inventory (CDI).

    Depressive symptoms will be assessed using the CDI. Higher scores indicate greater depressive symptomatology.

    Time frame: Baseline, week 5, and month 3.

  11. Change from baseline in anxiety assessed by the State-Trait Anxiety Inventory for Children (STAIC).

    Anxiety will be assessed using the STAIC. Higher scores indicate greater anxiety.

    Time frame: Baseline, week 5, and month 3.

  12. Change from baseline in executive function assessed by the Executive Function Inventory (EFE).

    Executive functioning will be assessed using the EFE. Higher scores indicate greater executive difficulties.

    Time frame: Baseline, week 5, and month 3.

  13. Change from baseline in health-related quality of life assessed by EQ-5D-Y-5L.

    Health-related quality of life will be assessed using the EQ-5D-Y-5L questionnaire. Higher index values indicate better perceived health status.

    Time frame: Baseline, week 5, and month 3.

  14. Change from baseline in caregiver burden assessed by the Zarit Burden Interview.

    Caregiver burden will be assessed using the Zarit Burden Interview. Higher scores indicate greater caregiver burden.

    Time frame: Baseline, week 5, and month 3.

  15. Pain intensity during rehabilitation sessions assessed by Visual Analog Scale (VAS).

    Pain intensity will be assessed using a VAS ranging from 0 (no pain) to 10 (worst possible pain). Higher scores indicate greater pain intensity.

    Time frame: During each intervention session (weeks 1-5).

  16. Fatigue during rehabilitation sessions assessed by EPInfant.

    Fatigue will be assessed using the EPInfant (Effort Perception for Children) scale during intervention sessions. Higher scores indicate greater perceived fatigue.

    Time frame: During each intervention session (weeks 1-5).

  17. Motor accuracy recorded by Inrobics Rehab Platform during intervention.

    Motor accuracy will be automatically recorded by the Inrobics Rehab digital platform during training sessions.

    Time frame: During each intervention session (weeks 1-5).

  18. Reaction time recorded by Inrobics Rehab Platform during intervention.

    Reaction time will be automatically recorded by the Inrobics Rehab digital platform during training sessions.

    Time frame: During each intervention session (weeks 1-5).

  19. Engagement recorded by Inrobics Rehab Platform during intervention

    Engagement will be automatically recorded by the Inrobics Rehab digital platform during training sessions.

    Time frame: During each intervention session (weeks 1-5)

  20. Performance per activity recorded by Inrobics Rehab Platform during intervention.

    Performance per activity will be automatically recorded by the Inrobics Rehab digital platform during training sessions.

    Time frame: During each intervention session (weeks 1-5).

  21. Execution speed recorded by Inrobics Rehab Platform during intervention.

    Execution speed will be automatically recorded by the Inrobics Rehab digital platform during training sessions.

    Time frame: During each intervention session (weeks 1-5).

  22. Heart Rate during hospital-based rehabilitation sessions

    Heart rate will be monitored using a Polar Verity Sense optical sensor during hospital-based rehabilitation sessions.

    Time frame: During hospital sessions (weeks 1-5).

  23. Engagement with the training program assessed by Hopkins Scale.

    Engagement with the training program will be assessed using the Hopkins scale at the end of the intervention.

    Time frame: Week 5.

  24. Satisfaction with the intervention assessed by Self-Assessment Manikin (SAM).

    Emotional response to the intervention will be assessed using the SAM.

    Time frame: Week 5.

  25. Change from baseline in satisfaction assessed by the Quebec User Evaluation of Satisfaction With Assistive Technology (QUEST 2.0).

    Satisfaction with assistive technology will be assessed using the QUEST 2.0, a standardized questionnaire evaluating user satisfaction with assistive devices and related services. Higher scores indicate greater satisfaction.

    Time frame: Week 5.

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be shared outside the study team. Access to data is restricted to the hospital and the consortium partner involved in the study, exclusively for the purposes of this research and under applicable data protection regulations. The data will not be used for other purposes, shared with third parties, or deposited in repositories. Only de-identified aggregate results will be reported in scientific publications.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2026 (actual). Primary completion is estimated for Feb 2027, 10 months after the start.

Of 285 non-industry interventional studies with no phase under Brain Injuries, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 50. This study's planned 10 months is below that.

Counting every sponsor, half of 298 studies reached it within 24 months; a quarter within 12 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 13, 2026
First posted
Mar 4, 2026
StartActual
Apr 27, 2026
Primary completionEst.
Feb 2027
CompletionEst.
Feb 2027
Last update
Jul 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07448103
Lead sponsor
Inrobics Social Robotics, S.L.
Collaborators
Fundación para la investigación biomética Hospital Infantil Universitario Niño Jesús, Hospital Infantil Universitario Niño Jesús, Madrid, Spain
Responsible party
Sponsor
First posted
Mar 4, 2026
Start date
Apr 27, 2026
Primary completion
Feb 2027 (estimated)
Completion
Feb 2027 (estimated)
Last update
Jul 23, 2026

Study contacts

José Carlos Pulido, Engineering
Contact
jcpulido@inrobics.com
+34 630423231
Fuensanta García, Medical device expert
Contact
fgarcia@inrobics.com
+34 630423231
Serafín Rodríguez
principal investigator · Hospital Infantil Universitario Niño Jesús

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion